



**A MULTIDISCIPLINARY
CALL TO ACTION**

HCC-LIVE 2025 Conference Agenda

February 20–22, 2025

Thursday, February 20, 2025:

6:30 PM – 8:30 PM: **Welcome Reception / Exhibit Hall / Poster Viewing**

Friday, February 21, 2025:

8:00 AM – 8:15 AM: **Welcome & Year in Review**
Anjana Pillai, MD

SESSION ONE

Is Two Really Better Than One: Role of Combination Therapies in the HCC Paradigm

Moderators: *Anthony El-Khoueiry, MD & Isabel G. Newton, MD, PhD*

8:15 AM – 8:25 AM: **Combination Therapy Synergistic vs. Additive: Lessons from the Lab**
Tim Greten, MD

8:25 AM – 8:35 AM: **Critical Assessment: LEAP-012**
Josep M. Llovet, MD, PhD, FAASLD

8:35 AM – 8:45 AM: **Critical Assessment: EMERALD -1**
Kirema Garcia-Reyes, MD

8:45 AM – 8:55 AM: **Does Radiation Therapy Have a Role in Combination Arms?**
Nina Sanford, MD

8:55 AM – 9:25 AM: **Panel Discussion/Q&A**

SESSION TWO

Life in the Fast Lane: Systemic Therapy Overload

Moderators: *Kristen Spencer, DO & TBD*

9:25 AM – 9:40 AM: **Systemic Therapy: Who's First?**
Kristen Spencer, DO

9:40 AM – 9:50 AM: **Take Two - Second Line Therapy and Beyond**
Anthony El-Khoueiry, MD

9:50 AM – 10:00 AM: **Is Three a Crowd? A Critical Review of Top 3 Triplet Mechanisms**
Mark Yarchoan, MD

10:00 AM – 10:10 AM: **Who's in Charge Here - What is the New Control Arm?**
Tanios Bekaii-Saab, MD, FACP





**A MULTIDISCIPLINARY
CALL TO ACTION**

10:10 AM – 10:40 AM: Panel Discussion/Q&A
10:40 AM – 11:10 AM: Break / Exhibit Hall / Poster Viewing

SESSION THREE
Moderator:

Oral Abstracts
Vatche G. Agopian, MD

11:10 AM – 11:20 AM: Oral Abstract
11:20 AM – 11:30 AM: Oral Abstract
11:30 AM – 12:00 PM: Panel Discussion/Q&A
12:00 PM – 12:10 PM: Lunch
12:10 PM – 12:55 PM: Industry-Sponsored Event

SESSION FOUR
Moderators:

HCC Biomarkers: Emerging Data and Clinical Integration
Amit Singal, MD, MS & Nicole Rich, MD, MS

12:55 PM – 1:05 PM: Treatment Selection Biomarkers - Where Do We Stand?
Augusto Villanueva, MD
1:05 PM – 1:15 PM: Emerging Surveillance Biomarkers
Neehar Parikh, MD, MS
1:15 PM – 1:25 PM: Minimal Residual Disease (MRD): Lessons Learned and Specific Applications
Yuxuan Wang, MD, PhD
1:25 PM – 1:55 PM: Panel Discussion/Q&A

SESSION FIVE
Panelists:

Tumor Board Part I
Richard Finn, MD; Edward Kim, MD; Neil Mehta, MD;
Parissa Tabrizian, MD; MSc, FACS; Adam Yopp, MD

2:00 PM – 2:30 PM: Case 1: *Anjana Pillai, MD*
2:30 PM – 3:00 PM: Case 2: *Riad Salem, MD, MBA*
3:00 PM – 3:30 PM: Panel Discussion/Q&A
3:30 PM – 3:40 PM: Day 1 Wrap-Up and Closing Remarks
5:45 PM – 6:30 PM: Industry-Sponsored Event





**A MULTIDISCIPLINARY
CALL TO ACTION**

6:30 PM – 8:30 PM: Faculty and Top Sponsor Reception

Saturday, February 22, 2025:

7:30 AM – 8:15 AM: Industry-Sponsored Event

**SESSION SIX
Moderator:**

Career Story
Riad Salem, MD, MBA

8:15 AM – 8:50 AM: Distinguished Lecture Series: A Career Story
Josep M. Llovet, MD, PhD, FAASLD

**SESSION SEVEN
Moderator:**

Patient Perspective Panel
Karim J. Halazun MD, FACS

8:50 AM – 8:55 AM: Introduction

8:55 AM – 9:15 AM: Our Story
Nick & Melissa Oprish

9:15 AM – 9:35 AM: Panel Discussion: Led by representatives from The Global Liver Institute and The Hepatitis B Foundation

9:35 AM – 10:00 AM: Break / Exhibit Hall / Poster Viewing

**SESSION EIGHT
Panelists:**

Tumor Board Part Two
Richard Finn, MD; Edward Kim, MD; Neil Mehta, MD;
Parissa Tabrizian, MD, MSc, FACS; Adam Yopp, MD

10:00 AM – 10:30 AM: Case 1: *Julie K. Heimbach, MD*

10:30 AM – 11:00 AM: Case 2: *Laura Kulik, MD*

11:00 AM – 11:30 AM: Panel Discussion/Q&A

11:30 AM – 11:45 AM: Lunch

11:45 AM – 12:30 PM: Industry-Sponsored Event

SESSION NINE

Hot Topics





**A MULTIDISCIPLINARY
CALL TO ACTION**

Moderators:

Parissa Tabrizian, MD, MSc, FACS & Mark Yarchoan, MD

12:30 PM – 12:40 PM: Surveillance, Diagnosis, and Risk Stratification of HCC in FALD
Maira Hilscher, MD

12:40 PM – 12:50 PM: LT for CRLM: An Update
Karim J. Halazun MD, FACS

12:50 PM – 1:00 PM: Utility of Neoadjuvant Therapy in Liver Resection: Locoregional
Robert Lewandowski, MD, FSIR

1:00 PM – 1:10 PM: Utility of Neoadjuvant Therapy in Liver Resection: Systemic
David Pinato, MD, PhD

1:10 PM – 1:40 PM Panel Discussion/Q&A

SESSION TEN

Moderators:

Debates

Anjana Pillai, MD & Laura Kulik, MD

1:40 PM – 2:05 PM: Resection vs. Systemic Therapy for Vp2
Gonzalo Sapisochin, MD vs. Adam Burgoyne, MD, PhD

2:05 PM – 2:30 PM: Who Does It Better? Downstaging to LT: Systemic or LRT
TBD vs. Sid Padia, MD

2:30 PM – 2:55 PM: Newer Kids on the Block: Histosonics vs. SBRT
Riad Salem, MD, MBA vs. Mishal Mendiratta-Lala, MD

2:55 PM – 3:00 PM: Day 2 Wrap-Up and Closing Remarks

